Table 4. Association between polymorphisms of estrogen metabolism-related genes related to estrogen metabolism and the risk of prostate cancer, by Gleason score and clinical stage, in the Afro-Caribbean population.
| Genes (allele) | Gleason Score | Clinical Stage | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Low Grade | High Grade | Localized | Advanced | ||||||
| Controls n (%) | Cases n (%) | Adjusted OR a (95% CI) | Cases n (%) | Adjusted OR a (95% CI) | Case n (%) | Adjusted OR a (95% CI) | Cases n (%) | Adjusted OR a (95% CI) | |
| CYP17(rs743572) | |||||||||
| T | 681 (64.5) | 434 (63.4) | 1.0 | 106 (65.8) | 1.0 | 476 (65.4) | 1.0 | 68 (59.6) | 1.0 |
| C | 375 (35.5) | 251 (36.4) | 0.99 (0.80–1.22) | 55 (34.2) | 0.86 (0.60–1.24) | 252 (34.6) | 0.92 (0.75–1.13) | 46 (40.4) | 1.06 (0.69–1.63) |
| CYP19 (rs60271534) | |||||||||
| ≤7 | 826 (79.1) | 540 (80.8) | 1.0 | 129 (77.7) | 1.0 | 562 (79.6) | 1.0 | 94 (81.0) | 1.0 |
| >7 | 218 (20.9) | 128 (19.2) | 0.80 (0.60–1.08) | 37 (22.3) | 0.99 (0.64–1.53) | 144 (20.4) | 0.84 (0.63–1.12) | 22 (19.0) | 0.83 (0.48–1.42) |
| CYP1B1 (rs1056836) | |||||||||
| C (Leu) | 289(26.4) | 177 (24.3) | 1.0 | 46 (28.1) | 1.0 | 188 (24.4) | 1.0 | 34(29.3) | 1.0 |
| G (Val) | 807(73.6) | 551 (75.7) | 1.04 (0.79–1.37) | 118 (71.9) | 0.89 (0.59–1.35) | 585 (75.6) | 1.04 (0.79–1.37) | 82 (70.7) | 0.80 (0.49–1.30) |
| COMT (rs4680) | |||||||||
| G (Val) | 712 (65.0) | 506 (69.5) | 1.0 | 107 (65.2) | 1.0 | 527 (68.4) | 1.0 | 83 (71.5) | 1.0 |
| A (Met) | 384 (35.0) | 222 (60.5) | 0.80 (0.64–0.98) | 57 (34.8) | 0.95 (0.66–1.35) | 243 (31.6) | 0.82 (0.67–1.01) | 33 (28.5) | 0.68 (0.43–1.07) |
| UGT1A1 (rs8175347) | |||||||||
| ≤ 6 | 588 (55.9) | 377 (55.3) | 1.0 | 86 (50.6) | 1.0 | 404 (55.8) | 1.0 | 56 (46.7) | 1.0 |
| > 6 | 464 (44.1) | 305 (44.7) | 1.20 (0.96–1.51) | 84 (49.4) | 1.48 (1.03–2.11) | 320 (44.2) | 1.19 (0.95–1.49) | 64 (53.3) | 1.59 (1.04–2.43) |
a Adjusted for age and education for CYP17 and COMT; for age, waist-to-hip-ratio and education for CYP19; for age, waist-to-hip-ration, type 2 diabetes, BMI, education and PSA screening history for CYP1B1; for age, education and waist-to-hip-ratio for UGT1A1.